Compare Stocks → Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACRSNASDAQ:ARQTOTCMKTS:INVVYNASDAQ:SAVA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.24+0.8%$1.22$0.59▼$11.12$87.95M0.221.53 million shs579,779 shsARQTArcutis Biotherapeutics$9.10-3.7%$10.06$1.76▼$15.21$880.97M1.144.78 million shs4.52 million shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsSAVACassava Sciences$19.64-7.3%$21.72$12.32▼$32.10$849.43M-0.45771,496 shs1.31 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%+0.82%+6.96%+7.89%-86.96%ARQTArcutis Biotherapeutics-7.80%-20.45%-4.16%+190.77%-30.46%INVVYIndivior0.00%0.00%0.00%0.00%+2.08%SAVACassava Sciences-0.38%-18.84%-3.64%-19.70%+22.84%Urgent alert: open this for a huge profit potential (Ad)This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.See Tim’s instructions to make this remarkably simple trade right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics1.4091 of 5 stars3.13.00.00.00.01.71.3ARQTArcutis Biotherapeutics1.546 of 5 stars3.41.00.00.01.92.50.6INVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.4912 of 5 stars3.51.00.04.73.00.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics2.14Hold$22.251,694.35% UpsideARQTArcutis Biotherapeutics2.75Moderate Buy$26.56191.82% UpsideINVVYIndiviorN/AN/AN/AN/ASAVACassava Sciences3.00Buy$124.00531.36% UpsideCurrent Analyst RatingsLatest ACRS, ARQT, SAVA, and INVVY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.002/23/2024ARQTArcutis BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $16.001/22/2024ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$31.25M2.81N/AN/A$2.22 per share0.56ARQTArcutis Biotherapeutics$59.61M14.78N/AN/A$0.94 per share9.68INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07SAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$88.48M-$1.27N/AN/AN/A-283.15%-64.56%-49.10%5/13/2024 (Estimated)ARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/ASAVACassava Sciences-$97.22M-$2.32N/A11.76N/AN/A-57.53%-52.58%5/6/2024 (Estimated)Latest ACRS, ARQT, SAVA, and INVVY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/A2/27/2024Q4 2023ACRSAclaris Therapeutics-$0.37-$0.30+$0.07-$0.58$3.96 million$17.57 million2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.164.16ARQTArcutis Biotherapeutics2.287.086.80INVVYIndiviorN/AN/AN/ASAVACassava SciencesN/A9.139.13OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%ARQTArcutis BiotherapeuticsN/AINVVYIndivior0.05%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.50%ARQTArcutis Biotherapeutics20.70%INVVYIndiviorN/ASAVACassava Sciences9.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics8670.93 million67.02 millionOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableACRS, ARQT, SAVA, and INVVY HeadlinesSourceHeadlineCassava Sciences (NASDAQ:SAVA) Shares Down 6% marketbeat.com - April 19 at 2:56 PMCassava Sciences, Inc. (SAVA)finance.yahoo.com - April 19 at 1:58 PMRail heralded as future for Thai logisticsbangkokpost.com - April 17 at 1:27 PMCassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher marketbeat.com - April 16 at 3:43 PMCassava Sciences (NASDAQ:SAVA) Sees Large Volume Increasemarketbeat.com - April 15 at 2:49 PMRedemption Date Announced for Warrantsglobenewswire.com - April 15 at 9:20 AMContrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)americanbankingnews.com - April 15 at 1:44 AMNicklaus: Path to world food security goes through St. Louisstltoday.com - April 14 at 7:17 AMCassava Sciences (NASDAQ:SAVA) Shares Down 9% americanbankingnews.com - April 14 at 4:42 AMCassava Sciences (NASDAQ:SAVA) Trading Down 9%marketbeat.com - April 12 at 2:51 PMVietnam has great potential for biofuel: expertsvietnamnet.vn - April 12 at 2:00 PMCassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA)americanbankingnews.com - April 12 at 3:52 AMInvestors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA)marketbeat.com - April 11 at 4:50 PMCassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volumemarketbeat.com - April 9 at 3:19 PMFosukrom farmers trained on organic herbicides, pesticidesmodernghana.com - April 8 at 8:15 PMZambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Futureinsideclimatenews.org - April 8 at 8:15 PMCassava Sciences (NASDAQ:SAVA) Trading Up 5.7%marketbeat.com - April 8 at 1:46 PMGates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africaagfundernews.com - April 5 at 2:17 AM5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Revealsfood.ndtv.com - April 5 at 1:13 AMAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesbizjournals.com - April 5 at 1:13 AMStrong quake rocks Taiwan, tsunami warnings issuedmsn.com - April 4 at 4:16 PMCan Africa one day help feed the world’s growing population?ft.com - April 3 at 3:22 AMElevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacymyjoyonline.com - April 2 at 5:22 PM24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassavastockhouse.com - April 2 at 5:22 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAclaris TherapeuticsNASDAQ:ACRSAclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Arcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.